Claritev just delivered Q2 results that management described as a validation of its multi-year turnaround, highlighted record first-half bookings, and raised full-year guidance. The stock surged nearly 20% on the news. On the surface, the story looks clean: revenue growth accelerating, cash flow improving, bookings targeting 50% growth over last year, and AI doing the heavy lifting.
Except there's a number on the balance sheet that changes how you read everything else.
The Business Is Fine. The Balance Sheet Isn't
Q2 2026 revenue came in at $257.5 million, up 6.6% from a year ago — the fifth consecutive quarter of year-over-year top-line growth. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization, a proxy for operational cash generation) was $155.8 million, essentially flat at 1.1% growth. The adjusted EBITDA margin compressed to 60.5% from 63.8% in Q2 2025.
The guidance raise was the headline mover: revenue lifted to $1 billion to $1.02 billion (from $985 million to $1 billion), adjusted EBITDA to $610 million to $620 million (from $605 million to $615 million), and free cash flow to $5 million to $15 million (from $0 to $10 million). Free cash flow for Q2 alone was $54.6 million, up from $36.6 million a year ago.
Quick Backtesting Tool
Those numbers are serviceable for a $980 million revenue business that is not leveraged. This one is.
Claritev carries $5.07 billion in total debt and holds $21.3 million in unrestricted cash. The market cap sits at $542 million. That means the enterprise value — what it would actually cost to buy the whole company — is roughly $5.2 billion, nearly ten times the equity value. Total shareholders' equity is negative $234 million. You're not looking at a company trading below its asset value. You're looking at a company whose shareholders own a deep out-of-the-money call on whether management can service that debt and have something left over.
The Interest Overhang Is the Real Story
Full-year 2025 interest expense was $392 million. Adjusted EBITDA for the same year was $602.6 million. About 65% of the company's operating cash generation goes to interest.
That leaves roughly $210 million of adjusted EBITDA to cover operating losses, capital expenditures, working capital needs, and any actual debt reduction. Full-year 2025 free cash flow was negative $12.3 million. The company burned cash despite generating $117.3 million in operating cash flow, because capital expenditures and interest obligations consumed everything.
The December 2024 refinancing pushed the nearest maturity to 2030 and the rest to 2031. That buys time. It doesn't eliminate the math. At current guidance levels, 2026 free cash flow of $5 million to $15 million is barely enough to cover the $20 million maximum in annual share repurchases that the board authorized, let alone make a dent in a $5 billion principal balance.
The debt-to-EBITDA ratio — total debt divided by trailing adjusted EBITDA — sits at roughly 8.3x. That is high for a company growing revenue at 5% to 6%. The refinancing bought maturity extension; it didn't buy rate relief. The new notes carry cash interest rates of 5.75% to 6.50%, plus payment-in-kind (PIK) components that accrue additional interest and grow the debt balance rather than reducing it.
Bookings Are Promising, Not Transformative
The $70 million in first-half bookings — heading toward the $100 million full-year target, a 50% increase over 2025 — is genuinely encouraging. Management described several seven-figure wins in the TPA (third-party administrator) market, including a significant deal with Marpi for payment and revenue integrity solutions.
But bookings are not revenue. Management acknowledged on the Q1 call that new bookings take six to twelve months to convert. The 2026 bookings are primarily a 2027 top-line signal. They also need to be weighed against revenue concentration risk: the company reported it had successfully renewed contracts with its ten largest clients, which is necessary but not extraordinary. The weighted average contract term for that group is over three years, which provides stability but doesn't immunize against churn when the broader environment shifts.
What About the AI Story?
Management is not bluffing about AI being a real operational lever. From the Q1 call: engineering teams have nearly doubled coding capacity without adding headcount. The company is shifting from a volume-based model toward complex, high-acuity claims that yield higher savings per claim. The Everest Group named ClaritevCTEV-- a "Leader" in its 2026 Pre-Payment Integrity Solutions assessment.
That said, AI is an efficiency multiplier, not a revenue engine at this stage. It helps preserve margins as the company scales. It doesn't replace the structural problem that 65% of operating cash generation goes to interest. The new services business from the OPCG acquisition runs at approximately half the margin profile of the core business, which is a headwind, not a tailwind, for adjusted EBITDA margins going forward.
The Price Action Is Already Running Ahead
Here's where the setup gets tricky. The stock jumped nearly 20% on earnings and was up roughly 40% over the prior five days. The year-to-date return, however, is still negative 25.6%, and the rolling one-year return is down 45%. The 52-week range is $11.50 to $74.07, and the current price of roughly $31.80 sits between the 50-day moving average of $28.62 and the 200-day moving average of $30.69.
The stock is showing momentum. The RSI at 63 is not overbought but is moving decisively higher. The MACD is still slightly negative, suggesting the trend has not fully confirmed. The amplitude and volatility figures — a 1-day volatility of 41.7% and a 36.7% intraday amplitude on earnings day — tell you this is a binary swing, not a steady compounding trade.
So What's the Verdict?
The operating business is solid. Revenue is growing. Cash flow conversion improved to 57% in Q2 from 47% a year ago. Bookings are setting up for a stronger 2027. Management executed a meaningful guidance raise.
But the valuation tells a different story. The stock trades at 0.55 times trailing revenue — which sounds cheap until you recognize that the equity value is a rounding error compared to enterprise value. You're paying $542 million for equity in a $5.2 billion enterprise. The shareholders' residual claim on this business is functionally negative on the balance sheet. The stock can go to zero if the debt loads compound faster than free cash flow can reduce them.
AInvest's aggregate signal labels the stock a Buy, driven by the strong cash-flow and liquidity metrics. That signal is looking at the operating business, which is competent. It isn't pricing in the balance-sheet risk that makes this a leveraged equity play, not a straightforward growth compounder.
I'm not chasing. The Q2 results and the guidance raise are real, but the stock's 40% five-day run has already priced in a material portion of the turnaround optimism. The risk/reward at current levels favors patience over conviction.
The better entry is on a pullback toward the 50-day moving average, if selling pressure emerges from investors who haven't yet absorbed what $5 billion of debt means for equity value. Or wait until the bookings pipeline actually converts to revenue in 2027 and the cash flow numbers prove they can sustainably service and reduce that debt.
I'd reassess my caution only if quarterly free cash flow consistently exceeds $50 million for two straight quarters and management provides a credible path to reduce total debt below $4 billion. Until then, this is a solid business wrapped in an overleveraged structure. The market doesn't always price that distinction correctly — but this time, it might be closer to right than the post-earnings rally suggests.
Don't let the AI narrative and the bookings headline distract from the arithmetic. The operating company is worth far more than the equity check reads. The question is whether you want to hold the equity check.
